Literature DB >> 17331912

Response to Food and Drug Administration draft guidance statement on research into the treatment of life-threatening emergency conditions using exception from informed consent: testimony of the neurological emergencies treatment trials.

Robert Silbergleit1.   

Abstract

Mesh：

Year:  2007        PMID： 17331912     DOI： 10.1197/j.aem.2006.12.004

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN： 1069-6563            Impact factor:   3.451


× No keyword cloud information.
  2 in total

1.  Variation of community consultation and public disclosure for a pediatric multi-centered "Exception from Informed Consent" trial.

Authors:  Maija Holsti; Roger Zemek; Jill Baren; Rachel M Stanley; Prashant Mahajan; Cheryl Vance; Kathleen M Brown; Victor Gonzalez; Denise King; Kammy Jacobsen; Kate Shreve; Katrina van de Bruinhorst; Anne Marie Jones; James M Chamberlain
Journal:  Clin Trials       Date:  2014-11-04       Impact factor: 2.486

2.  Intravenous levetiracetam versus phenobarbital in children with status epilepticus or acute repetitive seizures.

Authors:  Yun-Jeong Lee; Mi-Sun Yum; Eun-Hee Kim; Tae-Sung Ko
Journal:  Korean J Pediatr       Date:  2016-01-22
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.